Research studies are looking for volunteers just like you. Both healthy volunteers and participants with specific health conditions are needed to help answer important questions impacting the health of our friends and family. Join us to improve the health of others.

Study Categories

  • Evaluating an Investigational Hepatitis B Vaccine in Those Living with HIV

    Official Title
    “B-ENHANCEMENT OF HBV VACCINATION IN PERSONS LIVING WITH HIV (BEe-HIVe): Evaluation of HEPLISAV-B”
    Purpose

    The purpose of this study is to find out whether a hepatitis B vaccine called HEPLISAV-B is more effective at preventing hepatitis B infection in adults living with HIV than the current standard hepatitis B vaccine called ENGERIX-B. Vaccine side effects will also be studied.

    Participants will be on study for 72 weeks (almost 1.5 years).
    Overall, you may have up to 10 study visits.

    Could this study be right for you?

    - Living with HIV
    - On HIV treatment for more than 56 days
    - Previously received vaccines for hepatitis B, but the vaccines didn’t work
    - CD4 cell count (the number of white blood cells that fight infection) more than 100
    - HIV viral load (how much HIV is in the body) less than 1000

    Age Range
    18 and up
  • Evaluating if an Antiretroviral Therapy Medication Change Can Effect Weight

    Official Title
    “Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)”
    Purpose

    The purpose of this study is to see whether people living with HIV who gained a significant amount of weight after starting an antiretroviral therapy (ART) could gain less weight, or might lose weight, after an ART regimen switch.

    The study will also look at whether a switch in antiretroviral therapy leads to differences in how the body stores and uses energy, heart and blood vessel health, and bone health.

    The study will last for 48 weeks (about 1 year). Following the first visit, you will need to come back to the clinic after about 4, 12, 24, 36, and 48 weeks. Each visit may take up to 3 hours.

    Could this study be right for you?

    • Living with HIV-1
    • Be 18 years or older
    • Currently on an Integrase Inhibitor (INSTI) containing regimen (BIC, DTG or RAL), with > 48 weeks INSTI+TAF/FTC (or TAF/3TC) dosing prior to study entry
    • Have experienced more than 10% weight gain in the 1-3 years after starting these medications
    • Have a body mass index (BMI) >27.5 kg/m2
    • Have study related tests done
    • Agree to use contraception/birth control methods if capable of becoming pregnant

    Age Range
    18 and up
  • Evaluating the Anti-inflammation Effectiveness of a Medication in Adults with HIV-1 and Cytomegalovirus (CMV)

    Official Title
    A5383, Randomized, Controlled Trial to Evaluate the Antiinflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT)
    Purpose

    The purpose of this study is to evaluate whether letermovir (Prevymis), taken as two 240 mg tablets (480 mg total) or one 480 mg tablet once daily for 48 weeks, reduces inflammation in adults with human immunodeficiency virus (HIV-1) who also have cytomegalovirus (CMV) without any symptoms and who have been on effective anti-HIV medication for at least one year.

    Reducing inflammation might in turn help prevent some longer-term consequences of HIV, like heart disease and diabetes. This study will also look at whether you experience any side effects to the study drug.

    The study will last for about 1 year and 2 months (about 11 months on either letermovir or no anti-CMV study reatment and then about another 3 months of follow-up).

    Could this study be right for you?

    • HIV and CMV antibody positive
    •greater than or equal to 40 years of age
    • Not currently using any of the following ART medications: efavirenz, nevirapine, etravirine, lopinavir/ritonavir, or once a day dosing of raltegravir (twice daily OK)
    • Not pregnant or breastfeeding or planning to become pregnant during the study
    • No use of anti-CMV drugs within 90 days prior to study participation
    • No active HCV or HBV in past 24 weeks
    No presence or history of atrial or ventricular tachycardias
    • All gender identities are eligible, but there are enrollment targets for cis-women or transgender women on gender-affirming hormones

    Age Range
    40 and up
  • Evaluating the Effectiveness of a Study Drug and Quetiapine in People with Depression

    Official Title
    A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in people with Depression
    Purpose

    The purpose of this study is to see if a new drug (BI 1358894), taken in addition to a current antidepressant, is useful and safe for treating patients with Major Depressive Disorder.

    You will be in this study approximately 13 weeks and have about 8 visits to the study center. You will also have about 2 visits that will be done by phone.

    Could this study be right for you?

    Inclusion criteria:
    - Between the ages of 18 and 65
    - Currently taking an antidepressant
    - Currently experiencing symptoms of depression

    Age Range
    18 and up
  • Evaluating the Safety and Effectiveness of a Medication Used by Those Who have Sex with Male Partners and Are at Risk for HIV Infection

    Official Title
    A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV InfectionA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, for HIV Pre-Exposure to Those Having Sex with Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection
    Purpose

    The purpose of this study is to see if Lenacapavir is safe and effective to use as a pre-exposure prevention in Cisgender Men (CGM), Transgender Women (TGW), Transgender Men (TGM) and Gender Non-binary people (GNB), with a high risk of HIV infection.

    Could this study be right for you?

    • CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
    • HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months
    • Sexually active with ≥ 1 partner assigned male at birth in the last 12 months and 1 of the following:
    o Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks
    o History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks
    o Use of stimulants with sex in the last 12 weeks

    Age Range
    18 and up
  • Fertility and Contraception Among African Immigrants in the United States

    Official Title
    Fertility Desires and Demand for Modern Contraception Among African Immigrants in the United States
    Purpose

    The purpose of the study is to learn about how African immigrants make decisions about childbearing, both individually and as a couple, the role of modern contraception in helping them achieve their fertility desires and the effect of migration on their childbearing desires.

    Could this study be right for you?

    - Nigerian immigrant men and women of reproductive age (18-45 years) and,
    - Are in a relationship (dating, engaged or married)

    Age Range
    18 and up
  • Follow-up Study for Those Who Have Undergone (or Will Undergo) the Subchondroplasty (SCP) Knee Procedure

    Official Title
    KNEE CREATIONS SCP® OBSERVATIONAL COHORT FOLLOW-UP STUDY
    Purpose

    A study for those who will (have undergone) the Subchondroplasty (SCP) procedure for their knee. SCP is a procedure performed on subjects who have bone marrow lesions(BMLs). BMLs are subchondral defects in the bone, also called Insufficiency Fractures. This follow-up study will collect information on the short- and long-term safety and effectiveness of the SCP procedure.

    Could this study be right for you?

    - 18 years of age or older
    - Considered to be a candidate for SCP procedure by your surgeon
    - Have agreed to undergo the SCP procedure or has already undergone the procedure
    - Willing and able to sign a written consent form
    - Has the ability and the willingness to contribute follow-up outcome data

    Age Range
    18 and up
  • Immune Response in Adolescents

    Official Title
    Immune Response in Adolescents
    Purpose

    Our goal in this study is to learn more about the immune system in adolescence and early adulthood. We are looking to enroll healthy children ages 12-18 years old.

    Enrollment in the study will require 1 visit to Nationwide Children’s Hospital involving a blood draw and 2 nasal swabs.
    The visit will take approximately 1- 1 ½ hour(s). We ask that the family brings a copy of the child’s immunization record to the visit.

    Could this study be right for you?

    Children will need to meet the following criteria to be in the study:

    Inclusion Criteria:
    · Parents/Legal guardian able and willing to sign informed consent and the child is willing to sign assent form for participation. All forms are in English.
    · Healthy children, age 12-18 years old

    Exclusion Criteria:
    · Any chronic or congenital conditions that may potentially affect immune responses
    · Cough, congestion, fever, rhinorrhea, rash and any other symptoms indicative of infection within the 2 weeks prior to enrollment sampling
    · HIV, AIDS or other immunodeficiencies or any other condition that may affect their immune system
    · Use of systemic steroids within 2 weeks prior to enrollment
    · Immunization(s) within the last 30 days

    Age Range
    12 and up
  • Improving the Breast Cancer Care Delivery Model for Sex and Gender Minority Survivors (LGBTQ+)

    Official Title
    ImproviNg The BrEast CaNcer Care DelivEry MoDel for Sex and Gender Minority Survivors (INTENDED for SGM)
    Purpose

    The long-term goal of this study is to improve decision quality and health-related outcomes for sexual gender minority (SGM) breast/chest cancer survivors. The goal is to evaluate important ways the current care model needs adjusted for SGM people, and how best to combine a socially important care model into clinical practice.

    Survivors: Eligible participants will participate in a 90-minute focus group and online survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.

    Clinicians: Eligible participants will participate in a 30-minute interview and brief survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.

    Participation in this study will take no more than 1 hour and 30 minutes.

    Could this study be right for you?

    Survivors:
    1. Self-identify as a member of the SGM community
    2. Age ≥18 years at the time of signing the informed consent form
    3. Breast/chest cancer survivor in active treatment or completed active treatment in the last 10 years (not including hormone therapy)
    5. Be able to read and speak English
    6. Have received care in Ohio
    7. Be able to participate in virtual meetings

    Clinicians:
    1. Physicians, advance practice providers, nurses, psychologists, social workers, therapists, technologists, and other trained clinical professionals
    2. Provide care to individuals diagnosed with breast cancer in Ohio
    3. Be able to read and speak English
    4. Be able to participate in virtual meetings

    Age Range
    18 and up
  • Intervention to Improve Teen Driving

    Official Title
    A Hybrid Effectiveness-Implementation Trial to Improve Safe Driving among Teen Drivers with Traffic Violations
    Purpose

    The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent training, on parent-teen communications as well as teens' risky driving behaviors, unsafe driving behaviors, and subsequent traffic violations.

    Could this study be right for you?

    In order to be eligible:
    - You must be 16 -18 years of age
    - Need a valid State of Ohio driver's license (no learner's permit)
    - Proof of car insurance
    - Must drive more than one hour per week

    Age Range
    16 and up
  • Learning and Improving Alzheimer's Patient-Caregiver Relationships

    Official Title
    Collaborative Research: Learning and Improving Alzheimer's Patient-Caregiver Relationships via Smart Healthcare Technology
    Purpose

    The purpose of this study is to explore how family caregivers and persons with memory loss communicate and if certain ways of handling stress, such as mindfulness-based self managements, are helpful for family caregivers.

    You will be in the study for up to four months from the time of consent to the time of final study data collection. There will be 4 telephone or video calls, and each will take approximately 30 – 135 minutes.

    Could this study be right for you?

    Caregivers who will participate in this study need to:

    1) be aged 21 years or older
    2) be an informal, unpaid caregiver who lives with the care recipient
    3) be fluent in English
    4) have functioning home Wifi

    The inclusion criteria for care recipients (persons with memory loss) are:

    1) females and males age 60-99 years
    2) history of memory loss
    3) community-dwelling (living in the home)
    4) fluent in English

    Age Range
    21 and up
  • Lewy Bodies Study for Those with Sleep Behavior Disorders

    Official Title
    A Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) experiencing REM sleep behaviors (RBD)
    Purpose

    The purpose of this study is to evaluate the safety of the study drug called nelotanserin and to assess the effects of nelotanserin in those experiencing frequent REM sleep behavior disorders due to dementia with Lewy bodies. Nelotanserin (study drug) is an investigational product, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) or the government health agencies of any other countries.

    Could this study be right for you?

    --Age: 50-85
    --Diagnosis: probable dementia with Lewy bodies or Parkinson's disease dementia
    --AND diagnosis of REM sleep behavior disorder (RBD) with frequent RBD episodes
    --Must have a study partner willing to serve as a collateral informant for study assessments
    --MMSE Score: greater than or equal to 18 (Mini Mental State Examination score to be explained by the coordinator)

    Age Range
    50 and up